Research and Markets has announced the addition of the "Narcolepsy Pipeline Highlights - 2017" drug pipelines to their offering.

This report, Narcolepsy Pipeline Highlights - 2017, provides the most up-to-date information on key pipeline products in the global Narcolepsy market. It covers emerging therapies for Narcolepsy in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Narcolepsy pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Narcolepsy pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Narcolepsy pipeline products by the company.

Short-term Launch Highlights:

Find out which Narcolepsy pipeline products will be launched in the US and Ex-US till 2020.

Summary:

- Narcolepsy phase 3 clinical trial pipeline products

- Narcolepsy phase 2 clinical trial pipeline products

- Narcolepsy phase 1 clinical trial pipeline products

- Narcolepsy preclinical research pipeline products

- Narcolepsy discovery stage pipeline products

- Narcolepsy pipeline products short-term launch highlights

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/rrwzcl/narcolepsy